Pre-Open Stock Movers 07/26: (TYME) (MSTR) (FLOW) Higher; (ATIP) (ITRM) (TNXP) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Hasbro (HAS) Declares $0.68 Quarterly Dividend; 2.7% Yield
July 28, 2021 3:07 PM EDTHasbro (NASDAQ: HAS) declared a quarterly dividend of $0.68 per share, or $2.72 annualized.
The dividend will be payable on November 15, 2021, to stockholders of record on November 1, 2021, with an ex-dividend date of October 29, 2021.
The annual yield on the dividend is 2.7 percent.
For a... More
Hasbro (HAS) PT Raised to $128 at DA Davidson
July 27, 2021 8:39 AM EDTDA Davidson analyst Linda Bolton Weiser raised the price target on Hasbro (NASDAQ: HAS) to $128.00 (from $120.00) while maintaining a Buy rating.
The analyst commented, "HAS closed +12% on a big 2Q21 upside surprise, with sales +54% and +9% vs. 2Q19. HAS still expects double-digit sales... More
Hasbro (HAS) PT Raised to $120 at Jefferies
July 27, 2021 7:48 AM EDTJefferies analyst Stephanie Wissink raised the price target on Hasbro (NASDAQ: HAS) to $120.00 (from $115.00) while maintaining a Buy rating.
The analyst commented, "We see Q2 as a hallmark quarter, validating staying the course despite peripheral disruptions to the business. Sales & EBITDA handily... More
Tonix Pharma (TNXP) Acquires Infectious Disease R&D Facility
July 27, 2021 7:00 AM EDTTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) a clinical-stage biopharmaceutical company, today announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development (R&D) facility in Frederick, MD to support Tonixs expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.
Tonix agreed to purchase the R&D facility from Southern Research, a research collaboration partner... More

